SAN FRANCISCO -- The pediatric Crohn's disease exclusion diet was associated with clinical remission for children with good ...

A special liquid diet, known as exclusive enteral nutrition, is an essential therapy for Crohn's disease. Patients consume ...

Eli Lilly and Company (NYSE: LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of ...

Poster highlights robust, dose-dependent endoscopic response with VTX958 and reductions in key inflammatory markersFull analysis of Phase 2 ...

Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or ...

SAN FRANCISCO -- More adults with moderate-to-severe Crohn's disease (CD) reached clinical remission after 6 months on ...

92.9% maintained clinical remission at two years as measured by Crohn's Disease Activity Index (CDAI). Among patients treated in VIVID-2, 87.6% maintained endoscopic response, defined by visible ...

Eli Lilly And Cao (NYSE:LLY) announced the results from the VIVID-2 open-label extension study of Omvoh (mirikizumab-mrkz).

In a recent study published in the Journal of Crohn’s and Colitis, researchers showed that oral vancomycin (OV) induces clinical remission in primary sclerosing cholangitis-associated inflammatory ...

Eli Lilly has shared positive two-year results from an open-label extension (OLE) study of Omvoh (mirikizumab-mrkz) in active ...